Please assess the completion status of the following clinical trial:

Trial Title: Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals who aged 18 to 65 years~* Meet the diagnosis of schizophrenia according to DSM-IV~* Monotherapy of atypical antipsychotics for 4 weeks or more~* At least 60 for Positive and Negative Syndrome Scale (PANSS)~* Female subjects will be eligible to participate in the study if they are of non-childbearing potential or of child-bearing potential~* Sign the informed consent form~Exclusion Criteria:~* Individuals who with diagnosis of other psychiatric disorders except schizophrenia according to DSM-IV~* Refused to provide informed consent~* Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases~* Currently on anti-inflammatory or immunosuppressant medication including oral steroids and history of chronic infection (including tuberculosis, HIV and hepatitis), malignancy, organ transplantation, blood dyscrasia, central nervous system demyelinating disorder, and any other known autoimmune or inflammatory condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 62 Years
- Healthy Volunteers: f

Study Arms:
- berberine group (Type: EXPERIMENTAL): None
- control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).